Use of surrogate markers to predict the HIV disease stage and time to initiate antiretroviral therapy in developing countries

Journal of the International Association of Physicians in AIDS Care

Volumn 7, Issue 5, 2008, Pages 259-264

  Chaudhary, Monica ^a   Kashyap, Bineeta ^a   Gautam, Hitender ^a   Saini, Sanjeev ^a   Bhalla, Preena ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

b 2 microglobulin; HIV; surrogate markers; total lymphocyte count

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRY; DISEASE COURSE; DRUG ADMINISTRATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INDIA; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; VIROLOGY;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDIA; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; YOUNG ADULT;

EID: 59049091854     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109708322302     Document Type: Article

References (15)

1. Gupta SM, Ray K., Bala M. Evaluation of beta 2 microglobulin level as a marker to determine HIV/AIDS progression. J Commun Dis. 2004 ; 36: 166-170. (Pubitemid 43111048)
2. Sehgal S., Datta U., Mujtaba S., Sood A., Vinayak VK Cellular and serological markers of disease activity in Indian patients with HIV/AIDS. Methods Cell Sci. 2002 ; 24: 107-114. (Pubitemid 36826794)
3. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA. 1993 ; 269: 729-730.
4. Pascale JM, Isaacs MD, Contreras P., et al. Immunological markers of disease progression in patients infected with the Human Immunodeficiency Virus. Clin Diagn Lab Immunol. 1997 ; 4: 474-477. (Pubitemid 27321783)
5. Crowe S., Turnbull S., Oelrichs R., Dunne A. Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis. 2003 ; 37: s25 - s35.
6. Hosp M., Lisse IM, Quigley M., et al. An evaluation of low-cost progression markers in HIV-1 seropositive Zambians. HIV Med. 2000 ; 1: 125-127.
7. World Health Organization. Scaling Up Antiretroviral Therapy in Resource Limited Settings: Guidelines for a Public Health Approach. Geneva, Switzerland: World Health Organization ; 2003.
8. National AIDS Control Organization. Antiretroviral Therapy Guidelines for HIV Infected Adults and Adolescents Including Post Exposure Prophylaxis. New Delhi: Ministry of Health and Family Welfare, Government of India, National AIDS Control Organization ; 2007.
9. Moore DM, Awor A., Downing RS, et al. Determining eligibility for antiretroviral therapy in resource-limited settings using total lymphocyte counts, hemoglobin and body mass index. AIDS Res Ther. 2007 ; 4: 1-7.
10. Kumarasamy N., Mahajan AP, Flanigan TP, et al. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr. 2002 ; 31: 378-383. (Pubitemid 35397089)
11. Schreibman T., Friedland G. Use of total lymphocyte count for monitoring response to antiretroviral therapy. Clin Infect Dis. 2004 ; 38: 257-262. (Pubitemid 38113035)
12. Mahajan AP, Hogan JW, Synder B., et al. Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource limited settings. J Acquir Immune Defic Syndr. 2004 ; 36: 567-575. (Pubitemid 38544505)
13. Fahey JL Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection. Clin Diagn Lab Immunol. 1998 ; 5: 597-603. (Pubitemid 29030751)
14. Tsoukas CM, Bernard NF Markers predicting progression of human immunodeficiency virus-related disease. Clin Microbiol Rev. 1994 ; 7: 14-28. (Pubitemid 24038087)
15. O'Brien WA, Hartigan PM, Martin D., et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med. 1996 ; 334: 426-431. (Pubitemid 26055842)